SZSE:300026

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Tianjin Chase Sun PharmaceuticalLtd

Executive Summary

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. More Details


Snowflake Analysis

Adequate balance sheet with proven track record.


Similar Companies

Share Price & News

How has Tianjin Chase Sun PharmaceuticalLtd's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 300026 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 300026's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-3.9%

300026

-3.2%

CN Pharmaceuticals

-1.2%

CN Market


1 Year Return

18.9%

300026

25.5%

CN Pharmaceuticals

25.4%

CN Market

Return vs Industry: 300026 underperformed the CN Pharmaceuticals industry which returned 25.5% over the past year.

Return vs Market: 300026 underperformed the CN Market which returned 25.4% over the past year.


Shareholder returns

300026IndustryMarket
7 Day-3.9%-3.2%-1.2%
30 Day-6.0%-1.6%4.7%
90 Day-27.2%-1.9%6.7%
1 Year20.1%18.9%26.8%25.5%27.5%25.4%
3 Year3.2%1.1%29.2%24.5%23.2%17.0%
5 Year-13.7%-16.3%54.5%46.3%38.9%29.5%

Long-Term Price Volatility Vs. Market

How volatile is Tianjin Chase Sun PharmaceuticalLtd's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Tianjin Chase Sun PharmaceuticalLtd undervalued compared to its fair value and its price relative to the market?

25.78x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 300026 (CN¥4.4) is trading above our estimate of fair value (CN¥1)

Significantly Below Fair Value: 300026 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 300026 is good value based on its PE Ratio (25.8x) compared to the CN Pharmaceuticals industry average (30.5x).

PE vs Market: 300026 is good value based on its PE Ratio (25.8x) compared to the CN market (35x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 300026's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 300026 is good value based on its PB Ratio (1.8x) compared to the CN Pharmaceuticals industry average (2.7x).


Next Steps

Future Growth

How is Tianjin Chase Sun PharmaceuticalLtd forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tianjin Chase Sun PharmaceuticalLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Tianjin Chase Sun PharmaceuticalLtd performed over the past 5 years?

-13.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 300026 has high quality earnings.

Growing Profit Margin: 300026's current net profit margins (7.9%) are higher than last year (5.5%).


Past Earnings Growth Analysis

Earnings Trend: 300026's earnings have declined by 13.8% per year over the past 5 years.

Accelerating Growth: 300026's earnings growth over the past year (82.9%) exceeds its 5-year average (-13.8% per year).

Earnings vs Industry: 300026 earnings growth over the past year (82.9%) exceeded the Pharmaceuticals industry 11.9%.


Return on Equity

High ROE: 300026's Return on Equity (6.4%) is considered low.


Next Steps

Financial Health

How is Tianjin Chase Sun PharmaceuticalLtd's financial position?


Financial Position Analysis

Short Term Liabilities: 300026's short term assets (CN¥5.8B) exceed its short term liabilities (CN¥2.2B).

Long Term Liabilities: 300026's short term assets (CN¥5.8B) exceed its long term liabilities (CN¥451.7M).


Debt to Equity History and Analysis

Debt Level: 300026's debt to equity ratio (15.3%) is considered satisfactory.

Reducing Debt: 300026's debt to equity ratio has increased from 2.3% to 15.3% over the past 5 years.

Debt Coverage: 300026's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: 300026 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Tianjin Chase Sun PharmaceuticalLtd current dividend yield, its reliability and sustainability?

1.14%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 300026's dividend (1.14%) is higher than the bottom 25% of dividend payers in the CN market (0.4%).

High Dividend: 300026's dividend (1.14%) is low compared to the top 25% of dividend payers in the CN market (1.82%).


Stability and Growth of Payments

Stable Dividend: 300026's dividend payments have been volatile in the past 10 years.

Growing Dividend: 300026's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (29.3%), 300026's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average board tenure


CEO

Dan Zheng (55 yo)

no data

Tenure

CN¥2,608,400

Compensation

Ms. Dan Zheng serves as Director General & Vice Chairman at Tianjin Chase Sun Pharmaceutical Co.,Ltd. She served as Deputy General Manager and Secretary of The Board at Tianjin Chase Sun Pharmaceutical Co....


Board Members

NamePositionTenureCompensationOwnership
Dan Zheng
Director General & Vice Chairmanno dataCN¥2.61m0.088%
CN¥ 11.5m
Wu Jun Lan
Deputy GMno dataCN¥1.24m0.088%
CN¥ 11.5m
Yao Xiao Qing
Chairmanno dataCN¥2.81m3.43%
CN¥ 447.8m
Zantong Li
Directorno dataCN¥60.00kno data
Shu Li
Independent Director6.33yrsCN¥120.00kno data
Peng Fei Tu
Independent Director1yrno datano data
Da Wei Miao
Directorno dataCN¥449.20kno data
Pei Xun Liu
Chairman of the Supervisory Board1.75yrsCN¥58.50kno data
Shengtian Wang
Independent Director3.08yrsCN¥120.00kno data
Xu Feng Pu
Director1yrno datano data
Tao Gong
Independent Director1yrno datano data
Wu Sun
Director1.75yrsCN¥392.50kno data

1.8yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 300026's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Tianjin Chase Sun Pharmaceutical Co.,Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tianjin Chase Sun Pharmaceutical Co.,Ltd
  • Ticker: 300026
  • Exchange: SZSE
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥13.068b
  • Shares outstanding: 3.00b
  • Website: https://www.chasesun.cn

Number of Employees


Location

  • Tianjin Chase Sun Pharmaceutical Co.,Ltd
  • No. 20, Quanfa Road
  • Tianjin Wuqing Development Area
  • Tianjin
  • 10200536
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
300026SZSE (Shenzhen Stock Exchange)YesDomestic SharesCNCNYOct 2009
300026XSEC (Shenzhen Stock Exchange - Shenzhen-Hong Kong Stock Connect)YesDomestic SharesCNCNYOct 2009

Biography

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China. The company offers Chinese herb preparation products, m...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/18 09:11
End of Day Share Price2021/01/18 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.